» Articles » PMID: 24269966

A Novel Two-step Mild Hyperthermia for Advanced Liposomal Chemotherapy

Overview
Specialty Pharmacology
Date 2013 Nov 26
PMID 24269966
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Liposomal chemotherapy brings the advantage of minimizing systemic toxicity towards healthy organs and tissues, while has the drawbacks of limited nanoparticle accumulation and low drug bioavailability at targeted tumors. The aim of our study is to apply a clinically available mild hyperthermia (HT) treatment with thermosensitive liposomes (TSL) to tackle both issues. A two-step HT approach was combined with systemic administration of doxorubicin (Dox) TSL, in a first step to maximize nanoparticle accumulation in tumors and second step to actively trigger Dox release. The therapeutic activity of the two-step approach was compared to a one-step HT triggering intravascular Dox release from circulating TSL. Whereas the intravascular drug release approach requires fast releasing Dox-TSL (Dox-fTSL), the TSL formulation used in the two-step approach is fine-tuned to prolong Dox retention at physiological temperature in circulation, while releasing their drug content at mild HT at a slower rate (Dox-sTSL). Cytotoxicity assays show that a first-step HT at 41°C for 1h causes no drug resistance on murine BFS-1 sarcoma, human BLM melanoma cell lines and Human Umbilical Vein Endothelial Cells (HUVEC) towards subsequent exposure to Dox. However, HT sensitizes HUVEC towards Dox at higher concentrations (10-100μM). After 2h of intratumoral Dox-TSL accumulation, HT at 42°C for 1h was applied to trigger Dox release from Dox-sTSL. Quantification of intratumoral Dox accumulation revealed that the two-step HT approach increased TSL accumulation and Dox bioavailability reaching levels comparable to the intravascular release approach. The two-step HT in combination with Dox-sTSL delayed tumor growth for 12days compared to PBS group, however, was less effective compared to intravascular Dox release from Dox-fTSL using one-step HT. The two-step approach focuses on interstitial drug release upon mild HT, instead of intravascular drug release. This novel two-step approach represents an attractive alternative for the treatment of large and deep seated tumors, which are difficult to heat precisely and require loco-regional HT of the tumor area and accumulated Dox-sTSL therein to obtain a precise intratumoral drug delivery.

Citing Articles

Lipid-based nanosystems: the next generation of cancer immune therapy.

Cheng Z, Fobian S, Gurrieri E, Amin M, DAgostino V, Falahati M J Hematol Oncol. 2024; 17(1):53.

PMID: 39030582 PMC: 11265205. DOI: 10.1186/s13045-024-01574-1.


The Impact of Nanomedicine on Soft Tissue Sarcoma Treated by Radiotherapy and/or Hyperthermia: A Review.

Zachou M, Kouloulias V, Chalkia M, Efstathopoulos E, Platoni K Cancers (Basel). 2024; 16(2).

PMID: 38254881 PMC: 11154327. DOI: 10.3390/cancers16020393.


Recent Preclinical and Clinical Progress in Liposomal Doxorubicin.

Aloss K, Hamar P Pharmaceutics. 2023; 15(3).

PMID: 36986754 PMC: 10054554. DOI: 10.3390/pharmaceutics15030893.


Review of the Delivery Kinetics of Thermosensitive Liposomes.

Haemmerich D, Ramajayam K, Newton D Cancers (Basel). 2023; 15(2).

PMID: 36672347 PMC: 9856714. DOI: 10.3390/cancers15020398.


Liposomal Drug Delivery Systems for Cancer Therapy: The Rotterdam Experience.

Amin M, Seynhaeve A, Sharifi M, Falahati M, Ten Hagen T Pharmaceutics. 2022; 14(10).

PMID: 36297598 PMC: 9607095. DOI: 10.3390/pharmaceutics14102165.